Cyclo Therapeutics Equity Warrants Exp 14th Nov 2025 *W EXP 12/11/2025
Change company Symbol lookup
Select an option...
CYTHW Cyclo Therapeutics Equity Warrants Exp 14th Nov 2025 *W EXP 12/11/2025
FR First Industrial Realty Trust Inc
PNI PIMCO New York Municipal Income Fund II
NIB iPath? Bloomberg Cocoa Subindex Total Return(SM) ETN
DG Dollar General Corp
SPCO Stephan Co
KEX Kirby Corp
GM General Motors Co
F Ford Motor Co
MSFT Microsoft Corp
Go

Health Care : Biotechnology | Small Cap Value
Company profile

Cyclo Therapeutics, Inc. is a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease. The Company's lead drug candidate, Trappsol Cyclo (hydroxypropyl beta cyclodextrin) is for the treatment of Niemann-Pick Type C disease (NPC). NPC is a rare and fatal cholesterol metabolism disease that impacts the brain, lungs, liver, spleen, and other organs. It is also focusing on the use of cyclodextrins in the treatment of Alzheimer's disease. The Company's product lines include Trappsol and Aquaplex. It sells its chemical products directly to customers in the pharmaceutical, diagnostics, and industrial chemical industries, and to chemical supply distributors. The Company also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs.

Closing Price
$0.76
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.78
Day's Low
0.5088
Volume
(Above Average)
Volume:
1,592

10-day average volume:
1,592
1,592

MANTECH ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of MANT and Encourages Investors to Contact the Firm

4:18 pm ET May 24, 2022 (Globe Newswire) Print

EQNX::TICKER_START (NASDAQ:MANT),(NASDAQ:CG), EQNX::TICKER_END Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of ManTech International Corporation (NASDAQ: MANT) breached their fiduciary duties or violated the federal securities laws in connection with the company's acquisition by funds managed by Carlyle (NASDAQ: CG).

Click here to learn more and participate in the action.

On May 16, 2022, ManTech announced that it had entered into an agreement to be acquired by Carlyle in a deal valued at approximately $4.2 billion. Pursuant to the merger agreement, ManTech stockholders will receive $96 in cash for each share of ManTech common stock owned. The deal is scheduled to close in the second half of 2022.

Bragar Eagel & Squire is concerned that ManTech's board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for ManTech's stockholders.

If you own shares of ManTech and are concerned about the proposed merger, or you are interested in learning more about the investigation or your legal rights and remedies, please contact Melissa Fortunato by email at mergers@bespc.com or telephone at (646) 860-9157, or by filling out this contact form. There is no cost or obligation to you.

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact Information:

Bragar Eagel & Squire, P.C.

Melissa Fortunato, Esq.

mergers@bespc.com

www.bespc.com

https://ml.globenewswire.com/media/29481954-f2ff-4756-b5a9-d982a6497bd0/small/bes-mark-jpg.jpg

https://ml.globenewswire.com/media/29481954-f2ff-4756-b5a9-d982a6497bd0/small/bes-mark-jpg.jpg

comtex tracking

COMTEX_407702580/2010/2022-05-24T16:18:13

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.